What is 3T Biosciences?
3T Biosciences operates at the intersection of biotechnology and precision medicine, specializing in the development of next-generation immunotherapies. The company's core mission is to overcome the historical limitations of targeted biotherapeutics by utilizing a sophisticated discovery engine to identify previously inaccessible targets for cancer treatment. By focusing on solid tumors, 3T Biosciences is addressing one of the most significant challenges in modern oncology, aiming to provide durable, effective solutions for broad patient populations. Their platform is designed to enhance the specificity and efficacy of immune-mediated therapies, positioning the company as a high-potential player in the global biotech ecosystem.
How much funding has 3T Biosciences raised?
3T Biosciences has raised a total of $40.1M across 2 funding rounds:
Debt
$150K
Series A
$40M
Debt (2020): $150K with participation from PPP
Series A (2022): $40M led by Lightspeed Venture Partners and Westlake Village BioPartners
Key Investors in 3T Biosciences
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer, fintech, and infrastructure.
Westlake Village BioPartners
Westlake BioPartners is a life science venture capital firm focused on investing in world-class entrepreneurs to create innovative biotech companies that transform scientific breakthroughs into effective treatments.
PPP
Public-Private Partnership
What's next for 3T Biosciences?
With the recent influx of capital, 3T Biosciences is expected to prioritize the validation of its target discovery platform and the acceleration of its lead programs into clinical development. The strategic focus will likely shift toward establishing key partnerships and expanding its internal research team to maintain its competitive edge in the immunotherapy sector. As the company moves forward, the primary objective will be to translate its scientific breakthroughs into tangible clinical outcomes, potentially setting a new standard for the treatment of solid tumors. Investors will be closely monitoring the company's progress in navigating the regulatory landscape and achieving critical milestones in its upcoming clinical trials.
See full 3T Biosciences company page
